Longeveron Inc
LGVN0.558USD
+0.007+1.23%
Close 12/19, 16:00（ET）Quotes delayed by 15 min
11.75MMarket Cap
LossP/E TTM
More Details of Longeveron Inc Company
Longeveron Inc. is a clinical-stage biotechnology company developing regenerative medicines to address unmet medical needs. The Company’s lead investigational product is Lomecel-B, an allogeneic medicinal signaling cell (MSC) therapy product isolated from the bone marrow of young, healthy adult donors. Lomecel-B has multiple potential mechanisms of action, encompassing pro-vascular, pro-regenerative, anti-inflammatory, and tissue repair and healing effects with broad potential applications across a spectrum of disease areas. The Company is pursuing three pipeline indications: hypoplastic left heart syndrome (HLHS), Alzheimer’s disease, and Aging-related Frailty. Lomecel-B development programs have received five distinct FDA designations: for the HLHS program - Orphan Drug designation, Fast Track designation, and Rare Pediatric Disease designation; and, for the AD program - Regenerative Medicine Advanced Therapy (RMAT) designation and Fast Track designation.
Longeveron Inc Info
Ticker SymbolLGVN
Company nameLongeveron Inc
IPO dateFeb 12, 2021
CEOPowell (Than)
Number of employees25
Security typeOrdinary Share
Fiscal year-endFeb 12
Address1951 NW 7th Ave
CityMIAMI
Stock exchangeNASDAQ OMX - NASDAQ BASIC
CountryUnited States of America
Postal code33136
Phone13053027158
Websitehttps://www.longeveron.com/
Ticker SymbolLGVN
IPO dateFeb 12, 2021
CEOPowell (Than)
Company Executives of Longeveron Inc
Name
Name/Position
Position
Shareholding
Change
Dr. Joshua M. Hare, M.D.
Dr. Joshua M. Hare, M.D.
Executive Chairman of the Board, Co-Founder, Chief Science Officer
Executive Chairman of the Board, Co-Founder, Chief Science Officer
253.07K
-2.03%
Ms. Lisa Locklear
Ms. Lisa Locklear
Chief Financial Officer, Treasurer
Chief Financial Officer, Treasurer
152.42K
-7.23%
Dr. Nataliya Agafonova, M.D.
Dr. Nataliya Agafonova, M.D.
Chief Medical Officer
Chief Medical Officer
140.15K
-7.82%
Mr. Devin Blass
Mr. Devin Blass
Chief Technology Officer, Senior Vice President - Chemistry, Manufacturing, and Controls
Chief Technology Officer, Senior Vice President - Chemistry, Manufacturing, and Controls
102.54K
-6.91%
Ms. Ursula Ungaro, J.D.
Ms. Ursula Ungaro, J.D.
Independent Director
Independent Director
35.55K
+91.64%
Mr. Richard N. Kender
Mr. Richard N. Kender
Independent Director
Independent Director
22.33K
+318.71%
Mr. Roger Joseph Hajjar
Mr. Roger Joseph Hajjar
Independent Director
Independent Director
21.00K
+425.00%
Dr. George Paletta
Dr. George Paletta
Director
Director
--
--
Mr. Rock Soffer
Mr. Rock Soffer
Director
Director
--
--
Mr. Than Powell
Mr. Than Powell
Interim Chief Executive Officer
Interim Chief Executive Officer
--
--
View more
Name
Name/Position
Position
Shareholding
Change
Dr. Joshua M. Hare, M.D.
Dr. Joshua M. Hare, M.D.
Executive Chairman of the Board, Co-Founder, Chief Science Officer
Executive Chairman of the Board, Co-Founder, Chief Science Officer
253.07K
-2.03%
Ms. Lisa Locklear
Ms. Lisa Locklear
Chief Financial Officer, Treasurer
Chief Financial Officer, Treasurer
152.42K
-7.23%
Dr. Nataliya Agafonova, M.D.
Dr. Nataliya Agafonova, M.D.
Chief Medical Officer
Chief Medical Officer
140.15K
-7.82%
Mr. Devin Blass
Mr. Devin Blass
Chief Technology Officer, Senior Vice President - Chemistry, Manufacturing, and Controls
Chief Technology Officer, Senior Vice President - Chemistry, Manufacturing, and Controls
102.54K
-6.91%
Ms. Ursula Ungaro, J.D.
Ms. Ursula Ungaro, J.D.
Independent Director
Independent Director
35.55K
+91.64%
Mr. Richard N. Kender
Mr. Richard N. Kender
Independent Director
Independent Director
22.33K
+318.71%
Revenue Breakdown
Currency: USDUpdated: Mon, Oct 6
Currency: USDUpdated: Mon, Oct 6
FY2025Q2
FY2025Q1
FY2024Q3
FY2024Q2
FY2024Q1
FY2023
FY2023Q4
FY2023Q3
FY2023Q2
FY2023Q1
FY2022
FY2022Q4
FY2022Q3
FY2022Q2
FY2022Q1
FY2021
By BusinessUSD
Name
Revenue
Proportion
Clinical trial revenue
298.00K
94.30%
Contract manufacturing
12.00K
3.80%
Contract manufacturing lease revenue
6.00K
1.90%
Relevant data have not been disclosed by the company yet.
By Business
By Region
By BusinessUSD
Name
Revenue
Proportion
Clinical trial revenue
298.00K
94.30%
Contract manufacturing
12.00K
3.80%
Contract manufacturing lease revenue
6.00K
1.90%
Shareholding Stats
Updated: Sun, Nov 16
Updated: Sun, Nov 16
Shareholders
Shareholder Types
Shareholders
Shareholders
Proportion
Lincoln Alternative Strategies LLC
5.93%
Armistice Capital LLC
3.41%
The Vanguard Group, Inc.
2.55%
Lehr (Paul T)
1.64%
Hashad (Mohamed Wa'el Ahmed)
1.57%
Other
84.91%
Shareholders
Shareholders
Proportion
Lincoln Alternative Strategies LLC
5.93%
Armistice Capital LLC
3.41%
The Vanguard Group, Inc.
2.55%
Lehr (Paul T)
1.64%
Hashad (Mohamed Wa'el Ahmed)
1.57%
Other
84.91%
Shareholder Types
Shareholders
Proportion
Individual Investor
9.13%
Corporation
5.93%
Hedge Fund
3.77%
Investment Advisor
3.53%
Investment Advisor/Hedge Fund
1.08%
Research Firm
0.30%
Other
76.27%
Institutional Shareholding
Updated: Sun, Oct 5
Updated: Sun, Oct 5
Reporting Period
No. of institutions
Shares Held
Proportion
Change
2025Q3
58
1.73M
8.71%
+931.02K
2025Q2
73
2.18M
16.11%
+296.38K
2025Q1
73
2.14M
15.82%
-119.71K
2024Q4
73
2.53M
18.80%
+652.31K
2024Q3
67
2.33M
17.58%
+1.38M
2024Q2
67
924.88K
16.16%
+194.99K
2024Q1
64
168.05K
15.95%
-258.83K
2023Q4
68
363.47K
37.19%
+110.22K
2023Q3
73
198.13K
31.46%
-72.89K
2023Q2
70
193.49K
31.19%
-39.22K
View more
Shareholder Activity
Name
Shares Held
Proportion
Change
Chg %
Date
Lincoln Alternative Strategies LLC
1.18M
6.01%
+1.18M
--
Aug 08, 2025
Armistice Capital LLC
676.23K
3.45%
+676.23K
--
Sep 30, 2024
The Vanguard Group, Inc.
144.27K
0.74%
--
--
Jun 30, 2025
Lehr (Paul T)
330.30K
2.42%
+100.44K
+43.69%
Jul 15, 2025
Hashad (Mohamed Wa'el Ahmed)
310.90K
1.59%
+166.85K
+115.83%
Jul 15, 2025
Hare (Joshua M)
253.07K
1.29%
-5.25K
-2.03%
May 16, 2025
Soffer (Rock J)
179.52K
0.92%
+17.00K
+10.46%
Jul 15, 2025
Locklear (Lisa)
164.30K
0.85%
+11.77K
+7.71%
Aug 11, 2025
Geode Capital Management, L.L.C.
141.50K
0.72%
+770.00
+0.55%
Jun 30, 2025
Agafonova (Nataliya)
152.03K
1.12%
+94.57K
+164.57%
Jul 15, 2025
View more
Related ETFs
Updated: Sat, Dec 6
Updated: Sat, Dec 6
Name
Proportion
iShares Micro-Cap ETF
0%
iShares Micro-Cap ETF
Proportion0%
Dividend
A total of
0.00
USD has been distributed in dividends over the past 5 years.
Date
Dividend
Record Date
Payment Date
Ex-dividend Date
No Data
Stock Split
Date
Type
Ratio
Mar 19, 2024
Merger
10→1
Mar 19, 2024
Merger
10→1
Mar 19, 2024
Merger
10→1
Mar 19, 2024
Merger
10→1
Date
Type
Ratio
Mar 19, 2024
Merger
10→1
Mar 19, 2024
Merger
10→1
Mar 19, 2024
Merger
10→1
Mar 19, 2024
Merger
10→1
FAQs
Who are the top five shareholders of Longeveron Inc?
The top five shareholders of Longeveron Inc are:
Lincoln Alternative Strategies LLC holds 1.18M shares, accounting for 6.01% of the total shares.
Armistice Capital LLC holds 676.23K shares, accounting for 3.45% of the total shares.
The Vanguard Group, Inc. holds 144.27K shares, accounting for 0.74% of the total shares.
Lehr (Paul T) holds 330.30K shares, accounting for 2.42% of the total shares.
Hashad (Mohamed Wa'el Ahmed) holds 310.90K shares, accounting for 1.59% of the total shares.
Lincoln Alternative Strategies LLC holds 1.18M shares, accounting for 6.01% of the total shares.
Armistice Capital LLC holds 676.23K shares, accounting for 3.45% of the total shares.
The Vanguard Group, Inc. holds 144.27K shares, accounting for 0.74% of the total shares.
Lehr (Paul T) holds 330.30K shares, accounting for 2.42% of the total shares.
Hashad (Mohamed Wa'el Ahmed) holds 310.90K shares, accounting for 1.59% of the total shares.
What are the top three shareholder types of Longeveron Inc?
The top three shareholder types of Longeveron Inc are:
Lincoln Alternative Strategies LLC
Armistice Capital LLC
The Vanguard Group, Inc.
Lincoln Alternative Strategies LLC
Armistice Capital LLC
The Vanguard Group, Inc.
How many institutions hold shares of Longeveron Inc (LGVN)?
As of 2025Q3, 58 institutions hold shares of Longeveron Inc, with a combined market value of approximately 1.73M, accounting for 8.71% of the total shares. Compared to 2025Q2, institutional shareholding has increased by -7.41%.
What is the biggest source of revenue for Longeveron Inc?
In FY2025Q2, the Clinical trial revenue business generated the highest revenue for Longeveron Inc, amounting to 298.00K and accounting for 94.30% of total revenue.
